Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

Trevi Therapeutics, Inc.

Filed: Jun 3, 2026CIK: 0001563880
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Trevi Therapeutics stockholders approved amendments to the 2019 Stock Incentive Plan on June 3, 2026, increasing available shares by 8 million and implementing stricter compensation controls to align pay with performance and reduce shareholder dilution.

Key Takeaways

8,000,000 additional shares authorized for issuance under the amended 2019 Stock Incentive Plan

Non-employee director compensation has been limited to control costs and align with governance best practices

1 more takeaway

Filing Overview

Form Type8-K
Filing DateJun 3, 2026
Item5.02
CategoryExecutive Change
CIK0001563880
Accession #0001563880-26-000033
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
stock offeringregulatory

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings